End-of-Trial Drug Accountability: How to Close Out a Global Study Without a Compliance Gap

The last shipment out of a depot is the easy part. The hard part — the part inspectors will spend hours on — is proving you can account for every kit of investigational product that ever left the manufacturer. From first patient in to final destruction certificate, the chain of custody has to close cleanly. Sponsors who treat closeout as an administrative wrap-up end up with a good trial that finishes with a warning letter.

End-of-trial accountability is not a single event. It's a reconciliation that runs backward through every hand the drug passed through — patients to sites, sites to depots, depots to central return, central return to destruction. Any gap in that chain is a finding.

Why closeout gets rushed

By the time database lock is on the horizon, the operational team has been running the study for years and the sponsor's attention has moved on. Statistical analysis and clinical report writing take the oxygen. Meanwhile the supply chain team is being asked to close out sites in twenty countries, each with its own destruction rules, its own required documents, and its own timeline for regulatory return.

The result is predictable: sites left open for a year after last patient last visit because their drug reconciliation isn't clean, depots holding stock that nobody has authorized to destroy, and a compliance clock ticking in every jurisdiction.

The reconciliation math

Every unit of investigational product has to end up in one of four buckets: dispensed to a patient, returned to depot, destroyed with certification, or still on the shelf. The totals have to match manufacturing release records, unit for unit. Where kits are broken into strips or the drug is prepared in-clinic (dose banding, dilutions), the reconciliation happens at the level below the kit — and that is where most trials find they don't have the paperwork.

Do this math while the trial is running, not at closeout. A site with reconciliation drift of two percent at month twelve is a site with a serious problem at month thirty-six.

Checklist: Site-level accountability before closeout

Work through these at each site before signing off.

• Drug accountability log complete and legible. Every dispense, every return, every damaged or destroyed unit reconciled against IRT records and pharmacy stock counts.
• Temperature excursion log resolved. For every excursion during the trial, the CAPA is closed and the affected kits are either released or accounted for as destroyed.
• Unused stock returned or destroyed on approval. Do not leave partial kits sitting in a locked cupboard "in case." Regulators will find them.
• Patient-returned drug reconciled. Confirm counts match dispensed minus consumed. Sites underreport returns more often than they overreport them.
• Investigator has signed final accountability statement. Missing signatures at closeout are the single easiest audit finding to prevent.

Depot-level and return reconciliation

Central and regional depots hold the bulk stock that never made it to sites, plus incoming returns from those sites. Both flows have to reconcile to zero — or to a destruction certificate.

Do not accept a depot closeout summary that just gives you final numbers. Ask for the full ledger from initial receipt to final disposition, and spot-check three lots against IRT movement history.

• Returns from sites logged on arrival, quantity-checked before acceptance. A depot that only counts at destruction has no way to catch a discrepancy from a site.
• Blinded product handled without breaking the blind. Anyone who touches blinded returns needs an SOP that keeps them from seeing kit-level allocations.
• Import-country destruction rules confirmed before shipping stock home. Some regulators require destruction in-country. Discovering that at closeout costs weeks.

Destruction — who signs, and what you keep

A destruction certificate is not a receipt. It is a legal document that says a specific quantity of a specific lot of investigational product was destroyed on a specific date, by a specific licensed facility, in a specific manner. If any one of those five fields is missing, it will not stand up to inspection.

• Destruction facility is licensed for pharmaceutical waste in that country. Confirm current, not historical — licenses lapse.
• Certificates name the specific lot numbers and quantities destroyed. Generic "clinical trial supplies" language is not enough for GCP inspection.
• Sponsor keeps originals or certified copies in the trial master file. The depot's copy is not sufficient — the TMF must have its own.

The single most common inspection finding

Missing or incomplete drug accountability records at investigator sites. Not fraudulent — just incomplete. A dispensed unit whose return status is blank. A destroyed unit missing the pharmacist's signature. A returned unit that never made it into the site log.

These are trivial errors when they happen once. Multiplied across dozens of sites over years of accrual, they become the finding on the closeout letter.

What good looks like

A well-closed trial hands over a single reconciliation file per site and per depot, tied to the IRT audit trail, with destruction certificates attached and investigator signatures collected. Every unit released from manufacturing is accounted for. No open CAPAs. No unresolved excursions. No stock sitting somewhere it shouldn't.

You get there by treating accountability as a running discipline through the trial, not a task to complete at the end. The teams that get this right start reconciling at first patient in, and they never let a site drift for more than a quarter before catching up.